Literature DB >> 23135353

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation.

Y Chen1, H Kantarjian, S Pierce, S Faderl, S O'Brien, W Qiao, L Abruzzo, M de Lima, P Kebriaei, E Jabbour, N Daver, T Kadia, Z Estrov, G Garcia-Manero, J Cortes, F Ravandi.   

Abstract

The clinical features and outcomes of 148 patients with acute myeloid leukemia (AML) and 11q23 chromosomal abnormalities were compared with those of 2640 patients with non-11q23 AML. Patients with t(9;11) ), t(6;11) or other 11q23 balanced translocations (t(11;v)(q23;v)) presented at a younger age and with higher percentage of bone marrow blasts. Unbalanced 11q23 abnormalities were commonly associated with deletions of chromosomes 5q, 7q and/or complex karyotypes. In multivariate analysis, when compared with patients with non-11q23 AML and unfavorable-risk karyotype, there was a significant difference in overall survival (OS) for patients with t(9;11) (P=0.004), whereas there were no differences in OS for patients with t(6;11) (P=0.62), t(11;19) (P=0.20) and unbalanced 11q23 aberrations (P=0.85) or t(11;v)(q23;v) (P=0.59), indicating that t(9;11) has an independent intermediate prognostic significance, with all others being poor prognostic factors for OS; this was further confirmed by comparing them with patients with non-11q23 AML and intermediate-risk karyotype. Using intention-to treat analysis based on donor availability, we also noted that allogeneic stem cell transplant in first remission had a significant benefit toward improving OS (P<0.001) and relapse-free survival (P<0.001) in patients with AML and 11q23 abnormalities.

Entities:  

Mesh:

Year:  2012        PMID: 23135353      PMCID: PMC4181539          DOI: 10.1038/leu.2012.319

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  35 in total

1.  A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein.

Authors:  Daniel S Wechsler; Lars D Engstrom; Brian M Alexander; David G Motto; Diane Roulston
Journal:  Genes Chromosomes Cancer       Date:  2003-01       Impact factor: 5.006

Review 2.  The pathogenesis of mixed-lineage leukemia.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

3.  Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia.

Authors:  P J Kourlas; M P Strout; B Becknell; M L Veronese; C M Croce; K S Theil; R Krahe; T Ruutu; S Knuutila; C D Bloomfield; M A Caligiuri
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

4.  Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.

Authors:  K Mrózek; K Heinonen; D Lawrence; A J Carroll; P R Koduru; K W Rao; M P Strout; R E Hutchison; J O Moore; R J Mayer; C A Schiffer; C D Bloomfield
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

5.  Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.

Authors:  J Cortes; S O'Brien; H Kantarjian; A Cork; S Stass; E J Freireich; M Keating; S Pierce; E Estey
Journal:  Leukemia       Date:  1994-12       Impact factor: 11.528

6.  Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients.

Authors:  M Christina Cox; Paola Panetta; Francesco Lo-Coco; Giovanni Del Poeta; Adriano Venditti; Luca Maurillo; M Ilaria Del Principe; Alessandro Mauriello; Lucia Anemona; Antonio Bruno; Carla Mazzone; Paolo Palombo; Sergio Amadori
Journal:  Am J Clin Pathol       Date:  2004-08       Impact factor: 2.493

7.  11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia.

Authors:  C H Pui; F G Behm; J R Downing; M L Hancock; S A Shurtleff; R C Ribeiro; D R Head; H H Mahmoud; J T Sandlund; W L Furman
Journal:  J Clin Oncol       Date:  1994-05       Impact factor: 44.544

8.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

Review 9.  Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.

Authors:  William Blum; Krzysztof Mrózek; Amy S Ruppert; Andrew J Carroll; Kathleen W Rao; Mark J Pettenati; John Anastasi; Richard A Larson; Clara D Bloomfield
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

10.  AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.

Authors:  Claudia Schoch; Susanne Schnittger; Mirjam Klaus; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

View more
  19 in total

Review 1.  Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.

Authors:  Yahya Daneshbod; Leila Kohan; Vahideh Taghadosi; Olga K Weinberg; Daniel A Arber
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

2.  Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

Authors:  M A Kharfan-Dabaja; M Labopin; A Bazarbachi; R M Hamladji; D Blaise; G Socié; B Lioure; A Bermudez; L Lopez-Corral; R Or; W Arcese; N Fegueux; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-06-30       Impact factor: 5.483

3.  Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.

Authors:  Tomoya Muto; Masahiro Takeuchi; Atsuko Yamazaki; Yasumasa Sugita; Shokichi Tsukamoto; Shio Sakai; Yusuke Takeda; Naoya Mimura; Chikako Ohwada; Emiko Sakaida; Nobuyuki Aotsuka; Tohru Iseki; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2015-03-11       Impact factor: 2.490

4.  Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).

Authors:  A Pigneux; M Labopin; J Maertens; C Cordonnier; L Volin; G Socié; D Blaise; C Craddock; N Milpied; U Bacher; F Malard; J Esteve; A Nagler; M Mohty
Journal:  Leukemia       Date:  2015-06-17       Impact factor: 11.528

Review 5.  Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?

Authors:  Michael Heuser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 6.  Therapeutic implications of menin inhibition in acute leukemias.

Authors:  Ghayas C Issa; Farhad Ravandi; Courtney D DiNardo; Elias Jabbour; Hagop M Kantarjian; Michael Andreeff
Journal:  Leukemia       Date:  2021-06-15       Impact factor: 11.528

7.  11q23 abnormalities in adult Chinese patients with hematological malignancies.

Authors:  Xiaoli Zhao; Shuang Li; Nianyi Li; Rong Fan; Guowei Lin; Xiaoqin Wang
Journal:  Med Oncol       Date:  2014-07-10       Impact factor: 3.064

8.  Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A.

Authors:  Marius Bill; Krzysztof Mrózek; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Christopher J Walker; Deedra Nicolet; Dimitrios Papaioannou; James S Blachly; Shelley Orwick; Andrew J Carroll; Jonathan E Kolitz; Bayard L Powell; Richard M Stone; Albert de la Chapelle; John C Byrd; Clara D Bloomfield
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-05       Impact factor: 11.205

9.  Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).

Authors:  B Bhatnagar; J S Blachly; J Kohlschmidt; A-K Eisfeld; S Volinia; D Nicolet; A J Carroll; A W Block; J E Kolitz; R M Stone; K Mrózek; J C Byrd; C D Bloomfield
Journal:  Leukemia       Date:  2015-12-16       Impact factor: 11.528

Review 10.  Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.

Authors:  Nicole R Grieselhuber; Alice S Mims
Journal:  Curr Hematol Malig Rep       Date:  2021-03-18       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.